Pathophysiology of allergic inflammation

Immunological Reviews

Volumn 242, Issue 1, 2011, Pages 31-50

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Chemokines; Cytokines; Lipid mediators; T lymphocyte; Th2 cells

Indexed keywords

ACETYLSALICYLIC ACID; ANTIGEN; AUTOANTIBODY; CHEMOKINE; CORTICOSTEROID; CYTOKINE; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; JANUS KINASE; LIPID; MEPOLIZUMAB; NEUROPEPTIDE; NEUROTROPHIN; NITRIC OXIDE; PURINE; REACTIVE OXYGEN METABOLITE; STAT PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BASOPHIL; BREATHING MUSCLE; CLINICAL FEATURE; DENDRITIC CELL; DNA METHYLATION; DRUG MEGADOSE; DRUG TARGETING; EOSINOPHIL; EPIGENETICS; FIBROBLAST; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATION; LYMPHOCYTE; MAST CELL; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STRESS; TH2 CELL;

ADRENAL CORTEX HORMONES; ALLERGENS; ANIMALS; ANTI-INFLAMMATORY AGENTS; B-LYMPHOCYTES; CHILD; CYTOKINES; DENDRITIC CELLS; DNA METHYLATION; EOSINOPHILS; EPIGENOMICS; EPITHELIAL CELLS; FIBROBLASTS; GATA3 TRANSCRIPTION FACTOR; HISTONES; HUMANS; HYPERSENSITIVITY; INFLAMMATION; MAST CELLS; NEUTROPHILS; NF-KAPPA B; SUPERANTIGENS; TH2 CELLS;

EID: 79959334504     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2011.01020.x     Document Type: Article

References (208)

1. Akhabir L, Sandford AJ. Genome-wide association studies for discovery of genes involved in asthma. Respirology 2011;16:396-406.
2. Weidinger S, et al. Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. PLoS Genet 2008;4:e1000166.
3. Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol 2009;71:489-507.
4. Broide DH. Allergic rhinitis: pathophysiology. Allergy Asthma Proc 2010;31:370-374.
5. Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2009. J Allergy Clin Immunol 2010;125:85-97.
6. Leonardi-Bee J, Pritchard D, Britton J. Asthma and current intestinal parasite infection: systematic review and meta-analysis. Am J Respir Crit Care Med 2006;174:514-523.
7. Flohr C, Quinnell RJ, Britton J. Do helminth parasites protect against atopy and allergic disease? Clin Exp Allergy 2009;39:20-32.
8. Busse WW. The relationship of airway hyperresponsiveness and airway inflammation: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010;138:4S-10S.
9. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2006;533:327-340.
10. Jensen BM, Akin C, Gilfillan AM. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol 2008;154:1572-1582.
11. Ali FR, Kay AB, Larche M. Airway hyperresponsiveness and bronchial mucosal inflammation in T cell peptide-induced asthmatic reactions in atopic subjects. Thorax 2007;62:750-757.
12. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Immunol Rev 2008;8:183-192.
13. Lambrecht BN, Hammad H. The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. Lancet 2010;376:835-843.
14. Sokol CL, Chu NQ, Yu S, Nish SA, Laufer TM, Medzhitov R. Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nat Immunol 2009;10:713-720.
15. Yoshimoto T, et al. Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat Immunol 2009;10:706-712.
16. Nakanishi K. Basophils are potent antigen-presenting cells that selectively induce Th2 cells. Eur J Immunol 2010;40:1836-1842.
17. Saenz SA, Noti M, Artis D. Innate immune cell populations function as initiators and effectors in Th2 cytokine responses. Trends Immunol 2010;31:407-413.
18. Lloyd CM, Hessel EM. Functions of T cells in asthma: more than just T(H)2 cells. Nat Rev Immunol 2010;10:838-848.
19. Soroosh P, Doherty TA. Th9 and allergic disease. Immunology 2009;127:450-458.
20. Souwer Y, Szegedi K, Kapsenberg ML, de Jong EC. IL-17 and IL-22 in atopic allergic disease. Curr Opin Immunol 2010;22:821-826.
21. Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA. Role of Treg in immune regulation of allergic diseases. Eur J Immunol 2010;40:1232-1240.
22. Leckie MJ, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 2000;356:2144-2148.
23. Haldar P, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984.
24. Shamri R, Xenakis JJ, Spencer LA. Eosinophils in innate immunity: an evolving story. Cell Tissue Res 2011;343:57-83.
25. Halwani R, Al Muhsen S, Al Jahdali H, Hamid Q. Role of transforming growth factor-b in airway remodeling in asthma. Am J Respir Cell Mol Biol 2011;44:127-133.
26. Birring SS, Berry M, Brightling CE, Pavord ID. Eosinophilic bronchitis: clinical features, management and pathogenesis. Am J Respir Med 2003;2:169-173.
27. Nair P, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-993.
28. Drolet JP, Frangie H, Guay J, Hajoui O, Hamid Q, Mazer BD. B lymphocytes in inflammatory airway diseases. Clin Exp Allergy 2010;40:841-849.
29. Cameron L, et al. Local synthesis of epsilon germline gene transcripts, IL-4, and IL-13 in allergic nasal mucosa after ex vivo allergen exposure. J Allergy Clin Immunol 2000;106:46-52.
30. Takhar P, et al. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol 2007;119:213-218.
31. Lindell DM, Berlin AA, Schaller MA, Lukacs NW. B cell antigen presentation promotes Th2 responses and immunopathology during chronic allergic lung disease. PLoS ONE 2008;3:e3129.
32. Kato A, Xiao H, Chustz RT, Liu MC, Schleimer RP. Local release of B cell-activating factor of the TNF family after segmental allergen challenge of allergic subjects. J Allergy Clin Immunol 2009;123:369-375.
33. Cundall M, Sun Y, Miranda C, Trudeau JB, Barnes S, Wenzel SE. Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids. J Allergy Clin Immunol 2003;112:1064-1071.
34. Jatakanon A, Uasaf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999;160:1532-1539.
35. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006;11:54-61.
36. Alcorn JF, Crowe CR, Kolls JK. TH17 cells in asthma and COPD. Annu Rev Physiol 2010;72:495-516.
37. Doe C, et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 2010;138:1140-1147.
38. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003;112:252-262.
39. Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. Eur Respir J 2000;16:609-614.
40. Bachert C, Gevaert P, Zhang N, van Zele T, Perez-Novo C. Role of staphylococcal superantigens in airway disease. Chem Immunol Allergy 2007;93:214-236.
41. Bachert C, Zhang N, Patou J, van Zele T, Gevaert P. Role of staphylococcal superantigens in upper airway disease. Curr Opin Allergy Clin Immunol 2008;8:34-38.
42. Bachert C, Gevaert P, Holtappels G, Johansson SG, Van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol 2001;107:607-614.
43. Gould HJ, Takhar P, Harries HE, Chevretton E, Sutton BJ. The allergic march from Staphylococcus aureus superantigens to immunoglobulin E. Chem Immunol Allergy 2007;93:106-136.
44. Lee JY, et al. Role of staphylococcal superantigen-specific IgE antibodies in aspirin-intolerant asthma. Allergy Asthma Proc 2006;27:341-346.
45. Rocha-de-Souza CM, Berent-Maoz B, Mankuta D, Moses AE, Levi-Schaffer F. Human mast cell activation by Staphylococcus aureus: interleukin-8 and tumor necrosis factor alpha release and the role of Toll-like receptor 2 and CD48 molecules. Infect Immun 2008;76:4489-4497.
46. Barnes PJ. Intrinsic asthma: not so different from allergic asthma but driven by superantigens? Clin Exp Allergy 2009;39:1145-1151.
47. Fraser JD, Proft T. The bacterial superantigen and superantigen-like proteins. Immunol Rev 2008;225:226-243.
48. Herz U, et al. Airway exposure to bacterial superantigen (SEB) induces lymphocyte-dependent airway inflammation associated with increased airway responsiveness--a model for non-allergic asthma. Eur J Immunol 1999;29:1021-1031.
49. Seiberling KA, et al. Superantigens and chronic rhinosinusitis: detection of staphylococcal exotoxins in nasal polyps. Laryngoscope 2005;115:1580-1585.
50. Zhang N, et al. Mucosal tissue polyclonal IgE is functional in response to allergen and SEB. Allergy 2011;66:141-148.
51. Muralimohan G, Rossi RJ, Guernsey LA, Thrall RS, Vella AT. Inhalation of Staphylococcus aureus enterotoxin A induces IFN-gamma and CD8 T cell-dependent airway and interstitial lung pathology in mice. J Immunol 2008;181:3698-3705.
52. Patou J, Gevaert P, van Zele T, Holtappels G, Van Cauwenberge P, Bachert C. Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps. J Allergy Clin Immunol 2008;121:110-115.
53. Umibe T, et al. Clonal expansion of T cells infiltrating in the airways of non-atopic asthmatics. Clin Exp Immunol 2000;119:390-397.
54. Ou LS, Goleva E, Hall C, Leung DY. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 2004;113:756-763.
55. Cardona ID, Goleva E, Ou LS, Leung DY. Staphylococcal enterotoxin B inhibits regulatory T cells by inducing glucocorticoid-induced TNF receptor-related protein ligand on monocytes. J Allergy Clin Immunol 2006;117:688-695.
56. Li LB, Goleva E, Hall CF, Ou LS, Leung DY. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. J Allergy Clin Immunol 2004;114:1059-1069.
57. Zehn D, Bevan MJ, Fink PJ. Cutting edge: TCR revision affects predominantly Foxp3 cells and skews them toward the Th17 lineage. J Immunol 2007;179:5653-5657.
58. Eyerich K, et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol 2009;123:59-66.
59. Szczeklik A, Nizankowska E, Serafin A, Dyczek A, Duplaga M, Musial J. Autoimmune phenomena in bronchial asthma with special reference to aspirin intolerance. Am J Respir Crit Care Med 1995;152:1753-1756.
60. Sun RS, Chen XH, Liu RQ, Cheng TM, Ran XZ, Yang T. Autoantibodies to the high-affinity IgE receptor in patients with asthma. Asian Pac J Allergy Immunol 2008;26:19-22.
61. Nahm DH, et al. Identification of cytokeratin 18 as a bronchial epithelial autoantigen associated with nonallergic asthma. Am J Respir Crit Care Med 2002;165:1536-1539.
62. Nahm DH, Lee KH, Shin JY, Ye YM, Kang Y, Park HS. Identification of alpha-enolase as an autoantigen associated with severe asthma. J Allergy Clin Immunol 2006;118:376-381.
63. Kwon B, Lee HA, Choi GS, Ye YM, Nahm DH, Park HS. Increased IgG Antibody-Induced Cytotoxicity Against Airway Epithelial Cells in Patients with Nonallergic Asthma. J Clin Immunol 2009;29:517-523.
64. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998;50:515-596.
65. Wilson SJ, Lau L, Howarth PH. Inflammatory mediators in naturally occurring rhinitis. Clin Exp Allergy 1998;28:220-227.
66. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001;44:S1-S12.
67. van Ganse E, Kaufman L, Derde MP, Yernault JC, Delaunois L. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J 1997;10:2216-2224.
68. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007;357:1841-1854.
69. Boyce JA. Eicosanoids in asthma, allergic inflammation, and host defense. Curr Mol Med 2008;8:335-349.
70. Luster AD, Tager AM. T-cell trafficking in asthma: lipid mediators grease the way. Nat Rev Immunol 2004;4:711-724.
71. Gelfand EW, Dakhama A. CD8+ T lymphocytes and leukotriene B4: novel interactions in the persistence and progression of asthma. J Allergy Clin Immunol 2006;117:577-582.
72. Cho KJ, et al. Blockade of airway inflammation and hyperresponsiveness by inhibition of BLT2, a low-affinity leukotriene B4 receptor. Am J Respir Cell Mol Biol 2010;42:294-303.
73. Oguma T, Asano K, Ishizaka A. Role of prostaglandin D(2) and its receptors in the pathophysiology of asthma. Allergol Int 2008;57:307-312.
74. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007;6:313-325.
75. Schuligoi R, et al. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology 2010;85:372-382.
76. Grant GE, Rokach J, Powell WS. 5-Oxo-ETE and the OXE receptor. Prostaglandins Other Lipid Mediat 2009;89:98-104.
77. Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004;18:1791-1800.
78. Feltenmark S, et al. Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. Proc Natl Acad Sci U S A 2008;105:680-685.
79. Barnes PJ. Cytokine networks in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118:3546-3556.
80. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010;19:46-54.
81. Busse WW, Ring J, Huss-Marp J, Kahn JE. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol 2010;125:803-813.
82. Wenzel SE, et al. A randomized, double-blind, placebo-controlled study of TNF-a blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179:549-558.
83. Liu YJ. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med 2006;203:269-273.
84. Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol 2010;11:289-293.
85. Ying S, et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol 2005;174:8183-8190.
86. Mou Z, et al. Overexpression of thymic stromal lymphopoietin in allergic rhinitis. Acta Otolaryngol 2009;129:297-301.
87. Zhang Z, et al. Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc Natl Acad Sci USA 2009;106:1536-1541.
88. Barlow JL, McKenzie AN. IL-25: a key requirement for the regulation of type-2 immunity. Biofactors 2009;35:178-182.
89. Kurowska-Stolarska M, Hueber A, Stolarski B, McInnes IB. Interleukin-33: a novel mediator with a role in distinct disease pathologies. J Intern Med 2011;269:29-35.
90. Yagami A, et al. IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol 2010;185:5743-5750.
91. Kurowska-Stolarska M, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009;183:6469-6477.
92. Prefontaine D, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010;125:752-754.
93. Pushparaj PN, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A 2009;106:9773-9778.
94. Hsu CL, Neilsen CV, Bryce PJ. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS ONE 2010;5:e11944.
95. Wells TN, Power CA, Shaw JP, Proudfoot AE. Chemokine blockers-therapeutics in the making? Trends Pharmacol Sci 2006;27:41-47.
96. Gutierrez-Ramos JC, Lloyd C, Kapsenberg ML, Gonzalo JA, Coyle AJ. Non-redundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung. Immunol Rev 2000;177:31-42.
97. Erin EM, Williams TJ, Barnes PJ, Hansel TT. Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr Drug Targets Inflamm Allergy 2002;1:201-214.
98. Vijayanand P, et al. Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients. J Immunol 2010;184:4568-4574.
99. Montuschi P, et al. Increased 8-Isoprostane, a marker of oxidative stress, in exhaled condensates of asthmatic patients. Am J Respir Crit Care Med 1999;160:216-220.
100. Paredi P, Kharitonov SA, Barnes PJ. Elevation of exhaled ethane concentration in asthma. Am J Respir Crit Care Med 2000;162:1450-1454.
101. Barnes PJ. Reactive oxygen species in asthma. Eur Respir Rev 2000;10:240-243.
102. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol Rev 2004;84:731-765.
103. Barnes PJ, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010;138:682-692.
104. Kharitonov SA, Barnes PJ. Clinical aspects of exhaled nitric oxide. Eur Respir J 2000;16:781-792.
105. Kharitonov SA, Rajakulasingam K, O'Connor BJ, Durham SR, Barnes PJ. Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. J Allergy Clin Immunol 1997;99:58-64.
106. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001;163:1693-1772.
107. Hansel TT, et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J 2003;17:1298-1300.
108. Singh D, et al. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med 2007;176:988-993.
109. Lundberg JON, et al. High nitric oxide production in human paranasal sinuses. Nature Med 1995;1:370-373.
110. Polosa R, Blackburn MR. Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease. Trends Pharmacol Sci 2009;30:528-535.
111. Muller T, et al. A potential role for P2X7R in allergic airway inflammation in mice and humans. Am J Respir Cell Mol Biol 2011;44:456-464.
112. Idzko M, et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 2007;13:913-919.
113. Basoglu OK, Pelleg A, Essilfie-Quaye S, Brindicci C, Barnes PJ, Kharitonov SA. Effects of aerosolized adenosine 5'-triphosphate vs adenosine 5'-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma. Chest 2005;128:1905-1909.
114. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 2010;10:210-215.
115. Tschumperlin DJ, Drazen JM. Chronic effects of mechanical force on airways. Annu Rev Physiol 2006;68:563-583.
116. Hassan M, et al. Airway smooth muscle remodeling is a dynamic process in severe long-standing asthma. J Allergy Clin Immunol 2010;125:1037-1045.
117. Cox G. Bronchial thermoplasty for severe asthma. Curr Opin Pulm Med 2011;17:34-38.
118. Araya J, Nishimura SL. Fibrogenic reactions in lung disease. Annu Rev Pathol 2010;5:77-98.
119. Bergeron C, Al Ramli W, Hamid Q. Remodeling in asthma. Proc Am Thorac Soc 2009;6:301-305.
120. Aceves SS, Ackerman SJ. Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis. Immunol Allergy Clin North Am 2009;29:197-xiv.
121. Paredi P, Barnes PJ. The airway vasculature: recent advances and clinical implications. Thorax 2009;64:444-450.
122. Paredi P, Kharitonov SA, Barnes PJ. Correlation of exhaled breath temperature with bronchial blood flow in asthma. Respir Res 2005;6:15.
123. Siddiqui S, et al. Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis. J Allergy Clin Immunol 2007;120:813-819.
124. Walters EH, Reid D, Soltani A, Ward C. Angiogenesis: a potentially critical part of remodelling in chronic airway diseases? Pharmacol Ther 2008;118:128-137.
125. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2010;363:2233-2247.
126. Chen G, et al. SPDEF is required for mouse pulmonary goblet cell differentiation and regulates a network of genes associated with mucus production. J Clin Invest 2009;119:2914-2924.
127. Davis CW, Lazarowski E. Coupling of airway ciliary activity and mucin secretion to mechanical stresses by purinergic signaling. Respir Physiol Neurobiol 2008;163:208-213.
128. Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax 2004;59:992-996.
129. Joos GF, De Swert KO, Schelfhout V, Pauwels RA. The role of neural inflammation in asthma and chronic obstructive pulmonary disease. Ann NY Acad Sci 2003;992:218-230.
130. Barnes PJ. Neurogenic inflammation in the airways. Respir Physiol 2001;125:145-154.
131. Caceres AI, et al. A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. Proc Natl Acad Sci U S A 2009;106:9099-9104.
132. Lacroix JS, Landis BN. Neurogenic inflammation of the upper airway mucosa. Rhinology 2008;46:163-165.
133. Cevikbas F, Steinhoff A, Homey B, Steinhoff M. Neuroimmune interactions in allergic skin diseases. Curr Opin Allergy Clin Immunol 2007;7:365-373.
134. Kay AB. Calcitonin gene-related peptide- and vascular endothelial growth factor-positive inflammatory cells in late-phase allergic skin reactions in atopic subjects. J Allergy Clin Immunol 2011;127:232-237.
135. Freund-Michel V, Frossard N. The nerve growth factor and its receptors in airway inflammatory diseases. Pharmacol Ther 2008;117:52-76.
136. Raap U, Braunstahl GJ. The role of neurotrophins in the pathophysiology of allergic rhinitis. Curr Opin Allergy Clin Immunol 2010;10:8-13.
137. Borroni RG, Truzzi F, Pincelli C. The skin neurotrophic network in health and disease. Actas Dermosifiliogr 2009;100(Suppl.):70-74.
138. Fox AJ, Patel HJ, Barnes PJ, Belvisi MG. Release of nerve growth factor by human pulmonary epithelial cells: role in airway inflammatory diseases. Eur J Pharmacol 2001;424:159-162.
139. Nassenstein C, Kutschker J, Tumes D, Braun A. Neuro-immune interaction in allergic asthma: role of neurotrophins. Biochem Soc Trans 2006;34:591-593.
140. Watson JJ, et al. TrkAd5: a novel therapeutic agent for treatment of inflammatory pain and asthma. J Pharmacol Exp Ther 2006;316:1122-1129.
141. de Vries A, et al. Airway hyper-responsiveness in allergic asthma in guinea-pigs is mediated by nerve growth factor via the induction of substance P: a potential role for trkA. Clin Exp Allergy 2006;36:1192-1200.
142. Kassel O, et al. Local increase in the number of mast cells and expression of nerve growth factor in the bronchus of asthmatic patients after repeated inhalation of allergen at low-dose. Clin Exp Allergy 2001;31:1432-1440.
143. Veres TZ, Rochlitzer S, Braun A. The role of neuro-immune cross-talk in the regulation of inflammation and remodelling in asthma. Pharmacol Ther 2009;122:203-214.
144. Montoro J, et al. Stress and allergy. J Investig Allergol Clin Immunol 2009;19(Suppl.):40-47.
145. Arndt J, Smith N, Tausk F. Stress and atopic dermatitis. Curr Allergy Asthma Rep 2008;8:312-317.
146. Haczku A, Panettieri RA Jr. Social stress and asthma: the role of corticosteroid insensitivity. J Allergy Clin Immunol 2010;125:550-558.
147. Bailey MT, et al. Social stress enhances allergen-induced airway inflammation in mice and inhibits corticosteroid responsiveness of cytokine production. J Immunol 2009;182:7888-7896.
148. Quarcoo D, Pavlovic S, Joachim RA. Stress and airway reactivity in a murine model of allergic airway inflammation. Neuroimmunomodulation 2009;16:318-324.
149. Frew AJ, Plummeridge MJ. Alternative agents in asthma. J Allergy Clin Immunol 2001;108:3-10.
150. Barnes PJ. Transcription factors in airway diseases. Lab Invest 2006;86:867-872.
151. Barnes PJ, Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. New Engl J Med 1997;336:1066-1071.
152. Hart LA, Krishnan VL, Adcock IM, Barnes PJ, Chung KF. Activation and localization of transcription factor, nuclear factor-kB, in asthma. Am J Respir Crit Care Med 1998;158:1585-1592.
153. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005;25:552-563.
154. Adcock IM, Ford P, Barnes PJ, Ito K. Epigenetics and airways disease. Respir Res 2006;7:21.
155. Barnes PJ. How corticosteroids control inflammation. Br J Pharmacol 2006;148:245-254.
156. Ho IC, Pai SY. GATA-3 - not just for Th2 cells anymore. Cell Mol Immunol 2007;4:15-29.
157. Barnes PJ. Role of GATA-3 in allergic diseases. Curr Mol Med 2008;8:330-334.
158. Caramori G, et al. Expression of GATA family of transcription factors in T-cells, monocytes and bronchial biopsies. Eur Respir J 2001;18:466-473.
159. Nakamura Y, et al. Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J Allergy Clin Immunol 1999;103:215-222.
160. Maneechotesuwan K, et al. Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J Immunol 2007;178:2491-2498.
161. Finotto S, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 2002;295:336-338.
162. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 2005;307:430-433.
163. Yoshimoto T, Yoshimoto T, Yasuda K, Mizuguchi J, Nakanishi K. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J Immunol 2007;179:4415-4423.
164. Usui T, et al. T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. J Exp Med 2006;203:755-766.
165. Avni O, Lee D, Macian F, Szabo SJ, Glimcher LH, Rao A. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol 2002;3:643-651.
166. Maneechotesuwan K, et al. Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med 2009;6:e1000076.
167. Wang YH, et al. A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. J Exp Med 2010;207:2479-2491.
168. Pernis AB, Rothman PB. JAK-STAT signaling in asthma. J Clin Invest 2002;109:1279-1283.
169. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273-287.
170. Morales JK, Falanga YT, Depcrynski A, Fernando J, Ryan JJ. Mast cell homeostasis and the JAK-STAT pathway. Genes Immun 2010;11:599-608.
171. Wohlmann A, Sebastian K, Borowski A, Krause S, Friedrich K. Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function. Biol Chem 2010;391:181-186.
172. Knisz J, Rothman PB. Suppressor of cytokine signaling in allergic inflammation. J Allergy Clin Immunol 2007;119:739-745.
173. Schwartz DA. Epigenetics and environmental lung disease. Proc Am Thorac Soc 2010;7:123-125.
174. Ansel KM, Djuretic I, Tanasa B, Rao A. Regulation of Th2 differentiation and Il4 locus accessibility. Annu Rev Immunol 2006;24:607-656.
175. Lal G, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 2009;182:259-273.
176. Hollingsworth JW, et al. In utero supplementation with methyl donors enhances allergic airway disease in mice. J Clin Invest 2008;118:3462-3469.
177. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1b-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000;20:6891-6903.
178. Ito K, et al. Expression and activity of histone deacetylases (HDACs) in human asthmatic airways. Am J Respir Crit Care Med 2002;166:392-396.
179. Cosio BG, et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood monocytes in asthma. Am J Respir Crit Care Med 2004;170:141-147.
180. Hew M, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006;174:134-141.
181. Mattes J, Collison A, Plank M, Phipps S, Foster PS. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci U S A 2009;106:18704-18709.
182. Herrscher RF, Kasper C, Sullivan TJ. Endogenous cortisol regulates immunoglobulin E-dependent late phase reactions. J Clin Invest 1992;90:593-603.
183. Orsida BE, Krozowski ZS, Walters EH. Clinical relevance of airway 11beta-hydroxysteroid dehydrogenase type II enzyme in asthma. Am J Respir Crit Care Med 2002;165:1010-1014.
184. Barnes PJ, Lim S. Inhibitory cytokines in asthma. Mol Medicine Today 1998;4:452-458.
185. Wang CC, et al. Adenovirus expressing interleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma. Gene Ther 2006;13:1414-1421.
186. Sousa AR, Lane SJ, Nakhosteen JA, Lee TH, Poston RN. Expression of interleukin-1 beta (IL-1b) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med 1996;154:1061-1066.
187. Wills-Karp M. IL-12/IL-13 axis in allergic asthma. J Allergy Clin Immunol 2001;107:9-18.
188. Bryan S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyperreactivity and the late asthmatic response. Lancet 2000;356:2149-2153.
189. Naseer T, et al. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in reponse to steroids. Am J Resp Crit Care Med 1997;155:845-851.
190. Owaki T, et al. A role for IL-27 in early regulation of Th1 differentiation. J Immunol 2005;175:2191-2200.
191. Pretolani M, Goldman M. IL-10: a potential therapy for allergic inflammation? Immunol Today 1997;18:277-280.
192. John M, et al. Inhaled corticosteroids increase IL-10 but reduce MIP-1a, GM-CSF and IFN-g release from alveolar macrophages in asthma. Am J Respir Crit Care Med 1998;157:256-262.
193. Hawrylowicz CM. Regulatory T cells and IL-10 in allergic inflammation. J Exp Med 2005;202:1459-1463.
194. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707-713.
195. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008;121:1108-1111.
196. Pavord ID, Tattersfield AE. Bronchoprotective role for endogenous prostaglandin E2. Lancet 1995;344:436-438.
197. Levy BD. Lipoxins and lipoxin analogs in asthma. Prostaglandins Leukot Essent Fatty Acids 2005;73:231-237.
198. Planaguma A, et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008;178:574-582.
199. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008;9:873-879.
200. Aoki H, et al. Protective effect of resolvin E1 on the development of asthmatic airway inflammation. Biochem Biophys Res Commun 2010;400:128-133.
201. Levy BD, et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 2007;178:496-502.
202. Le AV, Broide DH. Indoleamine-2, 3-dioxygenase modulation of allergic immune responses. Curr Allergy Asthma Rep 2006;6:27-31.
203. Maneechotesuwan K, Supawita S, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids. J Allergy Clin Immunol 2008;121:43-50.
204. Maneechotesuwan K, et al. Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite-sensitive patients with asthma. J Allergy Clin Immunol 2009;123:239-248.
205. Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol 2010;126:754-762.
206. Barnes PJ. New drugs for asthma: is there any progress? Trends Pharmacol Sci 2010;31:335-343.
207. Barnes PJ. Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6:693-696.
208. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 2009;49:243-263.